Nuvation Bio Inc. (NYSE: NUVB) is a Healthcare company (Biotechnology) with a market capitalization of $1.4B. The Maz Rating grades it against the other companies in its sector.
Nuvation Bio Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.90, Nuvation Bio Inc. trades at 6.8x sales and 6.0x book value. Over the last twelve months it generated about $201M of revenue and a net loss of $139M. It runs a gross margin of 90.6%, an operating margin of -61.2% and a net margin of -67.4%. It shows return on equity of -49.1%, return on invested capital of -17.6% and a free cash flow yield of -7.9%. On the balance sheet: a debt-to-equity ratio of 2.05 and a current ratio of 7.45. Over the past 52 weeks the share price ranged from $3.79 to $9.75, with a beta of 1.73.
Nuvation Bio Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 8 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.